QBM076
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
March 28, 2022
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
(clinicaltrials.gov)
- P1 | N=298 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed
Combination therapy • Trial completion • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Immune Modulation • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer
October 25, 2021
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
(clinicaltrials.gov)
- P1; N=298; Active, not recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Aug 2022 ➔ Feb 2022; Trial primary completion date: Sep 2021 ➔ Dec 2021
Clinical • Combination therapy • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Immune Modulation • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CD8 • FOXP3
July 02, 2021
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
(clinicaltrials.gov)
- P1; N=298; Active, not recruiting; Sponsor: Novartis Pharmaceuticals; Recruiting ➔ Active, not recruiting
Enrollment closed • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Immune Modulation • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CD8 • FOXP3
May 05, 2021
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
(clinicaltrials.gov)
- P1; N=315; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Sep 2021 ➔ Aug 2022
Clinical • Combination therapy • Trial completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Immune Modulation • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CD8 • FOXP3
April 21, 2020
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
(clinicaltrials.gov)
- P1; N=315; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Feb 2021 ➔ May 2021; Trial primary completion date: Feb 2021 ➔ May 2021
Clinical • Combination therapy • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Immune Modulation • Immunology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thoracic Cancer • Triple Negative Breast Cancer • Urothelial Cancer
January 22, 2020
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
(clinicaltrials.gov)
- P1; N=315; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Dec 2019 ➔ Feb 2021; Trial primary completion date: Nov 2019 ➔ Feb 2021
Clinical • Combination therapy • Trial completion date • Trial primary completion date
1 to 6
Of
6
Go to page
1